0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover0.00%IV-489.97%PremiumAug 16, 2024Expiry Date3.32Intrinsic Value100Multiplier-7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Biora Therapeutics Stock Discussion
NaviCap™ Targeted Oral Delivery Platform and BT-600 in ulcerative colitis
Biora will present Phase 1 clinical trial data from the BT-600 program at the American College of Gastroenterology annual meeting in October, 2024.
Initiation of a Phase 1B clinical study in active ulcerative colitis patients is anticipated toward the end of 2024.
BioJet™ Systemic Oral Delive...
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics (Nasdaq: BIOR) presented supplemental data from the Phase 1 trial of BT-600, an orally administered drug-device combination for ulcerative colitis treatment, at a virtual KOL event. The trial results demonstrated that BT-600, using Biora's NaviCap™ platform, successfully delivered tofacitinib directly to the colon, achieving higher ti...
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative co...
BIVI(.49) I think has bottomed at .42 - Good adds here at .40s for a run to $1. Has a large gap to $1.76 which is high target. Can use the .42 as a safety for stop loss
BIOR(.70) Filed for mixed shelf offering two weeks ago, been trying to find these…HC Wainwright has $15 Target on it, don’t believe it but I do like it for gap fill to 1.08 minimum. I think this is going to get ran up and offering dropped. Should get dips t...
No comment yet